OraSure Technologies to Ring NASDAQ Stock Market Opening Bell in Honor of World AIDS Day
30 November 2018 - 12:33AM
OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of
care diagnostic tests and specimen collection devices, today
announced that Stephen S. Tang, Ph.D., President and CEO, will ring
the NASDAQ stock market opening bell on Monday, December 3, 2018 in
honor of World AIDS Day and the work OraSure is doing to end AIDS
on a global scale. The bell ringing will take place at 9:15 am EST.
“On the 30th anniversary of World AIDS Day, I am
reminded of how far we’ve come in the fight against HIV, yet there
is much more work to be done,” says Tang. “This year’s World AIDS
Day theme, ‘Know Your Status’ reflects the reality that, according
to the World Health Organization, one in four individuals with HIV
does not know they are infected. We must change the awareness
paradigm in order to reverse the course of this disease. Key to
fighting the disease is knowing your status through frequent
testing."
In honor of World AIDS Day, on November 30th,
Community Healthcare Network (CHN), one of the largest networks of
federally qualified health centers in New York City, will conduct a
large-scale testing event utilizing OraSure Technologies’ HIV tests
across its 15 health centers and mobile units around the city. By
administering HIV tests to patients and the general public, CHN
continues its commitment to providing underserved communities with
access to quality care.
Domestically and internationally, OraSure
employees are participating in testing efforts alongside their
customers. OraSure is also providing thousands of its HIV testing
devices to groups sponsoring awareness and testing events across
Africa, Asia and Europe.
For World AIDS Day and for the entire month of
December, OraSure will use a combination of social influencers and
digital media to reach at-risk consumers with a universal and
inclusive testing outreach program entitled “Together We Test”.
About Knowing PowerTang
continues, “OraQuick®, has been a game-changer not only here in the
United States, but for millions who live in places like Sub-Sahara
Africa where HIV and AIDS are still a major concern. In 2017 we
teamed up with the Bill & Melinda Gates Foundation to offer
affordable HIV Self-Testing to over 50 developing nations. We are
also dedicated to augmenting the fight through our ‘Knowing Power’
global initiative, which allocates funds from sales of OraQuick to
support new community testing pilot programs.”
The Knowing Power initiative was designed to get
testing kits directly into the hands of the previously untested.
For every OraQuick® test purchased between July 24 and December 1,
2018, OraSure is donating a portion of the sale to establish a
‘bank’ of OraQuick test devices. Both non-governmental
organizations and community groups have been engaged to help
distribute these kits into areas and validation programs that are
squarely aimed at ending the AIDS epidemic.
About OraSure Technologies HIV
TestsOraQuick ADVANCE® Rapid HIV-1/2 Antibody Test is the
first FDA approved, CLIA-waived, rapid point-of-care test that can
detect antibodies to both HIV-1 and HIV-2 with greater than 99%
accuracy in as little as 20 minutes, using an oral fluid,
finger-stick or venipuncture whole blood, or plasma sample.
The OraQuick® In-Home HIV Test is the first and
only oral fluid rapid OTC HIV test approved in the U.S. The
OraQuick® In-Home HIV Test can detect antibodies to both HIV-1 and
HIV-2 with an oral swab, providing a confidential in-home testing
option with results in as little as 20 minutes. It is the first
rapid diagnostic test for any infectious disease that has been
approved by the FDA for sale over the counter.
The OraQuick® HIV Self-Test (HIVST) is a
rapid, point-of-care test that allows an individual to detect
antibodies to both HIV-1 and HIV-2 with a simple oral swab and
provides a result in as little as 20 minutes in the privacy of an
individual’s home, at outreach testing settings, in the pharmacy or
at community based screening events. Based on the same
OraQuick® platform that is used for the FDA-approved OraQuick
In-Home HIV Test and the WHO Prequalified OraQuick Rapid HIV-1/2
Antibody Test used by health care professionals worldwide, the
platform has been used to test millions.
About OraSure
TechnologiesOraSure Technologies is a leader in the
development, manufacture and distribution of point-of-care
diagnostic and collection devices and other technologies designed
to detect or diagnose critical medical conditions. Its
first-to-market, innovative products include rapid tests for the
detection of antibodies to HIV and HCV on the OraQuick® platform,
oral fluid sample collection, stabilization and preparation
products for molecular diagnostic applications, and oral fluid
laboratory tests for detecting various drugs of abuse. OraSure's
portfolio of products is sold globally to various clinical
laboratories, hospitals, clinics, community-based organizations and
other public health organizations, research and academic
institutions, distributors, government agencies, physicians'
offices, commercial and industrial entities and consumers. The
Company's products enable healthcare providers to deliver critical
information to patients, empowering them to make decisions to
improve and protect their health. For more information on
OraSure Technologies, please visit www.orasure.com.
Following the bell ringing, OraSure Technologies
President and CEO, Stephen S. Tang, Ph.D., will be interviewed on
Facebook Live by the NASDAQ team. Check out Facebook.com/Nasdaq to
watch.
Media Contact:Jeanne MellVice President,
Corporate CommunicationsP: 610.882.1820E: media@orasure.com
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Apr 2024 to May 2024
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From May 2023 to May 2024